Clinical Trial Update: Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System Metastasis

View source ↗

Summary

The clinical trial evaluating Firmonertinib for EGFR-positive non-small cell lung cancer patients with central nervous system metastasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leptomeningeal Carcinomatosis
• Non-small Cell Lung Cancer

Drugs mentioned

• Firmonertinib (firmonertinib)

Snippet

Sponsor: Beijing Tiantan Hospital | Conditions: EGFR Positive Non-small Cell Lung Cancer, Central Nervous System Metastasis | Status: COMPLETED